Incidence and Pathogenesis of Thrombosis in Hematologic Malignancies

ABSTRACT

Recent surveys have indicated that thromboembolic complications are at least as common in hematologic malignancies, if not more frequent, than in solid tumors. The pathogenesis of thrombosis is similar to that in solid tumors, but with additional factors unique in several forms of hematologic malignancies, as seen in acute promyelocytic leukemia, myeloma, and myeloproliferative disorders. Likewise, the factors contributing to bleeding are similar to those seen in solid tumors, with the exception of a higher frequency of thrombocytopenia.

KEYWORDS

Leukemia - lymphoma - procoagulants - thrombosis - bleeding

REFERENCES

• 1 Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel-Dieu de Paris. Paris; Balliere 1865: 654-712
• 2 Bariety M. Tribute to Armand Trousseau (14 October 1801-23 June 1867).  Bull Acad Natl Med. 1967;  151(31) 627-635
• 3 Billroth T. Lectures on surgical pathology and therapeutics. In: A Handbook for Students and Practitioners. London; The New Sydenham Society 1878
• 4 Rickles F R, Levine M N. Epidemiology of thrombosis in cancer.  Acta Haematol. 2001;  106(1-2) 6-12
• 5 Tefferi A, Elliot M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.  Semin Thromb Hemost. 2007;  33 313-320
• 6 Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and in amyloidosis.  Semin Thromb Hemost. 2007;  33 339-349
• 7 White R H, Chew H K, Zhou H et al.. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults.  Arch Intern Med. 2005;  165(15) 1782-1787
• 8 De Stefano V, Sora F, Rossi E et al.. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.  J Thromb Haemost. 2005;  3(9) 1985-1992
• 9 Khorana A A, Francis C W, Culakova E, Fisher R I, Kuderer N M, Lyman G H. Thromboembolism in hospitalized neutropenic cancer patients.  J Clin Oncol. 2006;  24(3) 484-490
• 10 Blom J W, Doggen C J, Osanto S, Rosendaal F R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis.  JAMA. 2005;  293(6) 715-722
• 11 Sakuma M, Fukui S, Nakamura M et al.. Cancer and pulmonary embolism: thrombotic embolism, tumor embolism, and tumor invasion into a large vein.  Circ J. 2006;  70(6) 744-749
• 12 Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis.  Br J Cancer. 2005;  92(8) 1349-1351
• 13 Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma.  Cancer. 2003;  98(6) 1239-1242
• 14 Komrokji R S, Uppal N P, Khorana A A et al.. Venous thromboembolism in patients with diffuse large B-cell lymphoma.  Leuk Lymphoma. 2006;  47(6) 1029-1033
• 15 Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of venous thromboembolism in patients with acute leukaemia.  Br J Cancer. 2006;  94(2) 200-202
• 16 Ziegler S, Sperr W R, Knobl P et al.. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis.  Thromb Res. 2005;  115(1-2) 59-64
• 17 Virchow R. Phlogose und Thrombose in Gefabsystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen medizin. Frankfurt, Germany; Von Meidinger Sohn 1856: 458
• 18 Gale A J, Gordon S G. Update on tumor cell procoagulant factors.  Acta Haematol. 2001;  106(1-2) 25-32
• 19 Falanga A. Thrombophilia in cancer.  Semin Thromb Hemost. 2005;  31(1) 104-110
• 20 Kwaan H C, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis in cancer.  Semin Thromb Hemost. 2003;  29(3) 283-290
• 21 Negaard H, Dahm A, Sandset P M, Iversen P O, Ostenstad B. Angiogenesis and hemostasis in hematological neoplasias.  Curr Drug Targets. 2005;  6(6) 683-699
• 22 Rickles F R, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.  Int J Hematol. 2001;  73(2) 145-150
• 23 Bach R R. Tissue factor encryption.  Arterioscler Thromb Vasc Biol. 2006;  26(3) 456-461
• 24 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine.  Biochemistry. 1986;  25(14) 4007-4020
• 25 Kamikura Y, Wada H, Nobori T et al.. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism.  Thromb Res. 2005;  116(4) 307-312
• 26 Sase T, Wada H, Yamaguchi M et al.. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma.  Thromb Haemost. 2005;  93(1) 153-159
• 27 Kamikura Y, Wada H, Sase T et al.. Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy.  Thromb Res. 2006;  117(6) 671-679
• 28 Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.  Clin Chem Lab Med. 2000;  38(8) 679-692
• 29 Nadir Y, Katz T, Sarig G et al.. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.  Haematologica. 2005;  90(11) 1549-1556
• 30 Falanga A, Gordon S G. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.  Biochemistry. 1985;  24(20) 5558-5567
• 31 Falanga A, Consonni R, Marchetti M et al.. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells.  Blood. 1998;  92(1) 143-151
• 32 Olas B, Mielicki W P, Wachowicz B, Krajewski T. Cancer procoagulant stimulates platelet adhesion.  Thromb Res. 1999;  94(3) 199-203
• 33 Lisman T, de Groot P G, Meijers J C, Rosendaal F R. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis.  Blood. 2005;  105(3) 1102-1105
• 34 Lyons R M, Keski-Oja J, Moses H L. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.  J Cell Biol. 1988;  106(5) 1659-1665
• 35 Wilson E L, Jacobs P, Dowdle E B. The secretion of plasminogen activators by human myeloid leukemic cells in vitro.  Blood. 1983;  61(3) 568-574
• 36 Wilson E L, Jacobs P, Dowdle E B. The effects of dexamethasone and tetradecanoyl phorbol acetate on plasminogen activator release by human acute myeloid leukemia cells.  Blood. 1983;  61(3) 561-567
• 37 Cancelas J A, Garcia-Avello A, Garcia-Frade L J. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.  Thromb Res. 1994;  75(5) 513-520
• 38 Folsom A R, Cushman M, Heckbert S R, Rosamond W D, Aleksic N. Prospective study of fibrinolytic markers and venous thromboembolism.  J Clin Epidemiol. 2003;  56(6) 598-603
• 39 Martin S J, Reutelingsperger C P, McGahon A J et al.. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.  J Exp Med. 1995;  182(5) 1545-1556
• 40 Fadok V A, Voelker D R, Campbell P A, Cohen J J, Bratton D L, Henson P M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages.  J Immunol. 1992;  148(7) 2207-2216
• 41 Flynn P D, Byrne C D, Baglin T P, Weissberg P L, Bennett M R. Thrombin generation by apoptotic vascular smooth muscle cells.  Blood. 1997;  89(12) 4378-4384
• 42 Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus.  Proc Natl Acad Sci USA. 1996;  93(4) 1624-1629
• 43 Fibach E, Treves A, Korenberg A, Rachmilewitz E A. In vitro generation of procoagulant activity by leukemic promyelocytes in response to cytotoxic drugs.  Am J Hematol. 1985;  20(3) 257-265
• 44 Wang J, Weiss I, Svoboda K, Kwaan H C. Thrombogenic role of cells undergoing apoptosis.  Br J Haematol. 2001;  115(2) 382-391
• 45 Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia.  Blood. 1998;  91(9) 3093-3102
• 46 Tallman M S, Lefebvre P, Baine R M et al.. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.  J Thromb Haemost. 2004;  2(8) 1341-1350
• 47 Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer.  Thromb Res. 2001;  102(6) V215-V224
• 48 Brusselmans K, Bono F, Collen D, Herbert J M, Carmeliet P, Dewerchin M. A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia.  J Biol Chem. 2005;  280(5) 3493-3499
• 49 Yan S F, Mackman N, Kisiel W, Stern D M, Pinsky D J. Hypoxia/hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis.  Arterioscler Thromb Vasc Biol. 1999;  19(9) 2029-2035
• 50 Anderson K C. The role of immunomodulatory drugs in multiple myeloma.  Semin Hematol. 2003;  40(4 suppl 4) 23-32
• 51 Anderson K C. Moving disease biology from the lab to the clinic.  Cancer. 2003;  97(3 suppl) 796-801
• 52 Anderson K C, Pazdur R, Farrell A T. Development of effective new treatments for multiple myeloma.  J Clin Oncol. 2005;  23(28) 7207-7211
• 53 Chauhan D, Uchiyama H, Akbarali Y et al.. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.  Blood. 1996;  87(3) 1104-1112
• 54 Urashima M, Ogata A, Chauhan D et al.. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.  Blood. 1996;  87(5) 1928-1938
• 55 Podar K, Tai Y T, Davies F E et al.. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.  Blood. 2001;  98(2) 428-435
• 56 Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson K C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.  Oncogene. 2001;  20(33) 4519-4527
• 57 Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V. Blood cells diseases and thrombosis.  Haematologica. 2001;  86(12) 1236-1244
• 58 de Gaetano G, Cerletti C, Evangelista V. Recent advances in platelet-polymorphonuclear leukocyte interaction.  Haemostasis. 1999;  29(1) 41-49
• 59 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism.  Lancet Oncol. 2005;  6(6) 401-410
• 60 Beer J H, Haeberli A, Vogt A et al.. Coagulation markers predict survival in cancer patients.  Thromb Haemost. 2002;  88(5) 745-749
• 61 Goldenberg N, Kahn S R, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism.  J Clin Oncol. 2003;  21(22) 4194-4199
• 62 Blann A D, Gurney D, Wadley M, Bareford D, Stonelake P, Lip G Y. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor.  Blood Coagul Fibrinolysis. 2001;  12(1) 43-50
• 63 Simak J, Gelderman M P. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers.  Transfus Med Rev. 2006;  20(1) 1-26
• 64 Horstman L L, Jy W, Jimenez J J, Bidot C, Ahn Y S. New horizons in the analysis of circulating cell-derived microparticles.  Keio J Med. 2004;  53(4) 210-230
• 65 Dixit A, Kannan M, Mahapatra M, Choudhry V P, Saxena R. Roles of protein C, protein S, and antithrombin III in acute leukemia.  Am J Hematol. 2006;  81(3) 171-174
• 66 Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.  Am J Med. 2001;  110(2) 91-96
• 67 Sarig G, Michaeli Y, Lanir N, Brenner B, Haim N. Mechanisms for acquired activated protein C resistance in cancer patients.  J Thromb Haemost. 2005;  3(3) 589-590
• 68 Green D, Maliekel K, Sushko E, Akhtar R, Soff G A. Activated-protein-C resistance in cancer patients.  Haemostasis. 1997;  27(3) 112-118
• 69 Kwaan H C, Bongu A. The hyperviscosity syndromes.  Semin Thromb Hemost. 1999;  25(2) 199-208
• 70 Cukierman T, Gatt M E, Libster D, Goldschmidt N, Matzner Y. Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein.  Leuk Lymphoma. 2002;  43(9) 1865-1868
• 71 Khorana A A, Francis C W, Culakova E, Lyman G H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.  Cancer. 2005;  104(12) 2822-2829
• 72 Chang V T, Aviv H, Howard L M, Padberg F. Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature.  Am J Hematol. 2003;  72(1) 20-26
• 73 Colovic N, Miljic P, Colovic M, Milosevic-Jovcic N. Multiple M components in two patients with splenic lymphoma with villous lymphocytes.  Ann Hematol. 2006;  85(1) 51-54
• 74 Gomez-Puerta J A, Cervera R, Espinosa G et al.. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients.  Semin Arthritis Rheum. 2006;  35(5) 322-332
• 75 Genvresse I, Luftner D, Spath-Schwalbe E, Buttgereit F. Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma.  Eur J Haematol. 2002;  68(2) 84-90
• 76 Pusterla S, Previtali S, Marziali S et al.. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance.  Hematol J. 2004;  5(4) 341-346
• 77 Khan S, Dickerman J D. Hereditary thrombophilia.  Thromb J. 2006;  4 15
• 78 Simioni P, Tormene D, Spiezia L et al.. Inherited thrombophilia and venous thromboembolism.  Semin Thromb Hemost. 2006;  32(7) 700-708
• 79 Leroyer C, Mercier B, Oger E et al.. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients.  Thromb Haemost. 1998;  80(1) 49-51
• 80 Abramson N, Costantino J P, Garber J E, Berliner N, Wickerham D L, Wolmark N. Effect of Factor V Leiden and prothrombin G20210→A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.  J Natl Cancer Inst. 2006;  98(13) 904-910
• 81 Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.  Br J Haematol. 2006;  134(4) 399-405
• 82 Di Micco P, Niglio A, De Renzo A et al.. Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report.  J Transl Med. 2004;  2(1) 7
• 83 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.  J Clin Oncol. 2003;  21(19) 3665-3675
• 84 Cortelezzi A, Moia M, Falanga A et al.. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study.  Br J Haematol. 2005;  129(6) 811-817
• 85 Svensson M, Wiren M, Kimby E, Hagglund H. Portal vein thrombosis is a common complication following splenectomy in patients with malignant haematological diseases.  Eur J Haematol. 2006;  77(3) 203-209
• 86 Mohren M, Markmann I, Dworschak U et al.. Thromboembolic complications after splenectomy for hematologic diseases.  Am J Hematol. 2004;  76(2) 143-147
• 87 Zakarija A, Kwaan H C. Adverse effects on hemostatic function caused by drugs used in hematologic malignancies.  Semin Thromb Hemost. 2007;  33 355-364
• 88 Webert K, Cook R J, Sigouin C S, Rebulla P, Heddle N M. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia.  Haematologica. 2006;  91(11) 1530-1537
• 89 Spectre G, Libster D, Grisariu S et al.. Bleeding, obstruction, and perforation in a series of patients with aggressive gastric lymphoma treated with primary chemotherapy.  Ann Surg Oncol. 2006;  13(11) 1372-1378
• 90 Deshpande A, Storch I, Barkin J. Diagnosis of lymphoma in overt obscure GI bleeding aided by capsule endoscopy.  Gastrointest Endosc. 2007;  65(1) 159-160
• 91 Koornstra J J, Schot B W, Dijkstra G. Mantle cell lymphoma involving the appendiceal orifice as an unusual cause of lower gastrointestinal bleeding.  Int J Colorectal Dis. 2007;  22(1) 99-100
• 92 Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases.  Am J Hematol. 2000;  65(3) 215-222
• 93 Menell J S, Cesarman G M, Jacovina A T, McLaughlin M A, Lev E A, Hajjar K A. Annexin II and bleeding in acute promyelocytic leukemia.  N Engl J Med. 1999;  340(13) 994-1004
• 94 Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors.  Blood. 1994;  83(7) 1883-1891
• 95 Kwaan H C, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin.  J Thromb Haemost. 2004;  2(2) 306-312
• 96 Dally N, Hoffman R, Haddad N, Sarig G, Rowe J M, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients.  Thromb Res. 2005;  116(2) 109-114
• 97 Boggio L N, Green D. Acquired hemophilia.  Rev Clin Exp Hematol. 2001;  5(4) 389-404
• 98 Collins P W, Hirsch S, Baglin T P et al.. Acquired haemophilia A in the UK: a two year national surveillance study by UK Haemophilia Centre Doctors' Organisation.  Blood. 2007;  109 1870-1877
• 99 Sallah S, Wan J Y. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients.  Cancer. 2001;  91(6) 1067-1074
• 100 Sallah S, Nguyen N P, Abdallah J M, Hanrahan L R. Acquired hemophilia in patients with hematologic malignancies.  Arch Pathol Lab Med. 2000;  124(5) 730-734